NWBO made a big mistake raising cash with free warrants to sweeten any deal as affectively you can back a horse both ways and it's allowed a hedge fund(s) to damage the business by shorting stock so that you end up where we are today. A real case of smashing up a car to buy it cheaply. However make no mistake the net result is increasing their long position at a frankly crazy low price and they have and will make money both ways. AF's article today is not a million miles from the truth and no doubt now the raise has gone through it's obvious and unsubtle to see his strategy change to one mocking the deal ( the irony eh ) he has played his part in this saga!
The losers are and have been retail investors scared off by a sinking share price that has been based on nothing more than city wise guys doing their job. The clinical results are clear for all to see and that must remain the end game in terms of delivering shareholder value. Solid news will be out very soon and I hope that will be a trigger to convince large institutional investors to finally back this baby!
I'm putting my cock on the block and saying news around German revenue is very close!
All in all a rubbish day but stick to the science and the clinical facts already published and NWBO will deliver a very healthy return.
I understand your frustration but there is something to be said for letting the data mature given this is only in a Phase I. I'm not sure if you have unrealistic expectations on the timing of the Direct trial?
As you are aware I had a long conversation with LG about 1 week ago and I laid out per my conversation what we should expect by years end and an update on the Direct trial is part of that.
The hammering that this pps has taken sucks for everyone in the moment its happening and your watching your $ value dropping. But...do you not believe that the science is sound and given proper time will prove to be successful? If your answer to this is NO, then this was always a swing position for you in a very risky sector. GLTU
Please! Yes, it's an open trial, as you said. So how, in the same breath, can you say insiders are not buying? What would you have to say if insiders who knew about the Direct results thus far, while the shareholders didn't, bought shares? You'd be okay with that?
News 
Market Data 
Discover 
AI
